William Shanahan has joined the board of Life Technologies, the company said this week. His appointment became effective Dec. 16.
Shanahan is the former president of Colgate-Palmolive and currently serves on the boards of Visa, Diageo, and MSD Ignition.
Richard Schifreen has become the president and CEO of Platypus Technologies, the company said this week. His appointment became effective Dec. 10.
Schifreen was formerly vice president of research products at Mirus Bio in Madison, Wisc. Before that, he was director of technology and business development at Promega. He was also a founding faculty for the Masters of Science in Biotechnology Program at the University of Wisconsin School of Medicine and Public Health.
He replaces Jeffrey Williams who left to pursue opportunities in molecular biology, Platypus said in a statement.
Contract research organization Covance this week named Thomas Turi its vice president of biomarkers, where he will responsible for building the company’s Biomarker Center of Excellence.
He will also lead the CRO’s Biomarker Expert Team, made up of scientists “representing Covance’s biomarker capabilities,” the company said in a statement.
The plans for the center of excellence were announced this week along with the acquisition of a minority stake in biomarker firm Caprion Proteomics [see story in briefs, this issue].
Turi joins Covance from Pfizer where he was senior director of translational biomarkers and mechanistic biology at the drug firm’s laboratories in Groton, Conn.
HistoRx this week said it appointed Kathleen Adams as vice president of diagnostics marketing, a newly created position. The company also retained Stephen Chubb as a strategic advisor.
Adams had been marketing director of new technology planning and research for Quest Diagnostics. Before that, she was director of oncology marketing at the company. She also has held various product management positions at Parke-Davis Pharmaceuticals, Schering-Plough, and Genetics Institute, now part of Wyeth.
Chubb will help HistoRx identify and assess business development initiatives and opportunities. He was founder, chairman, and CEO of Matritech before it was sold to Milano Acquisition, a subsidiary of Inverness Medical Innovations, earlier this year. Prior to that, he was CEO and chairman of T Cell Sciences, and CEO and chairman of Cytogen.